NSAID-gastroenteropathy: New aspects of pathogenesis and prevention

Current Opinion in Pharmacology

Volumn 19, Issue , 2014, Pages 11-16

  Blackler, Rory W ^a   Gemici, Burcu ^b   Manko, Anna ^a   Wallace, John L ^c,d  

^a MCMASTER UNIVERSITY   (Canada)

^b NEAR EAST UNIVERSITY   (Turkey)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTHIOBENZAMIDE; ACETYLSALICYLIC ACID; ATB 346; BICARBONATE; CELECOXIB; DICLOFENAC; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROGEN SULFIDE; INDOMETACIN; IRSOGLADINE MALEATE; KETOPROFEN; MISOPROSTOL; NAPROXEN; NAPROXEN DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; REBAMIPIDE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL OVERGROWTH; BILE; CHEMOPROPHYLAXIS; DRUG ABSORPTION; DRUG EFFECT; DRUG INDUCED DISEASE; DYSBIOSIS; ENTEROBACTERIACEAE; ENTEROHEPATIC CIRCULATION; GASTROINTESTINAL DISEASE; HUMAN; INTESTINAL BLEEDING; INTESTINE ABSORPTION; INTESTINE INJURY; INTESTINE ULCER; LOW DRUG DOSE; NONHUMAN; NSAID ENTEROPATHY; PATHOGENESIS; PRIORITY JOURNAL; STOMACH ACID SECRETION; STOMACH PROTECTION; ANIMAL; CHEMICALLY INDUCED; GASTROINTESTINAL DISEASES; METABOLISM; BIFIDOBACTERIUM; DISEASE EXACERBATION; GASTROINTESTINAL SYMPTOM; NSAID GASTROENTEROPATHY; PROTECTION; REVIEW; STOMACH INJURY; ULCER;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GASTROINTESTINAL DISEASES; HUMANS; PROTON PUMP INHIBITORS;

EID: 84902466865     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2014.05.008     Document Type: Review

References (34)

1. J.L. Wallace NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct preventions strategies Br J Pharmacol 165 2012 67 74
2. J.L. Wallace, S. Syer, E. Denou, G. de Palma, L. Vong, W. McKnight, J. Jury, M. Bolla, P. Bercik, S.M. Collins, E. Verdu, and E. Ongini Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis Gastroenterology 141 2011 1314 1322
3. H. Satoh, K. Amagase, and K. Takeuchi Exacerbation of nonsteroidal anti-inflammatory drug-induced small intestinal lesions by antisecretory drugs in rats: the role of intestinal motility J Pharmacol Exp Ther 343 2012 270 277
4. A. Lanas, L.A. GarcIa-RodrIguez, M. Polo-Tomas, M. Ponce, I. Alonso-Abreu, M.A. Perez-Aisa, J. Perez-Gisbert, L. Bujanda, M. Castro, M. Muñoz, L. Rodrigo, X. Calvet, D. Del-Pino, and S. Garcia Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice Am J Gastroenterol 104 2009 1633 1641
5. J.L. Wallace Polypharmacy of osteoarthritis: the perfect intestinal storm Dig Dis Sci 58 2013 3088 3093
6. J.L. Wallace Physiological and pathophysiological roles of hydrogen sulfide in the gastrointestinal tract Antioxid Redox Signal 12 2010 1125 1133
7. S.A. Mard, N. Neisi, G. Solgi, M. Hassanpour, M. Darbor, and M. Maleki Gastroprotective effect of NaHS against mucosal lesions induced by ischemia-reperfusion injury in rat Dig Dis Sci 57 2012 1496 1503
8. S. Fiorucci, E. Antonelli, E. Distrutti, G. Rizzo, A. Mencarelli, S. Orlandi, R. Zanardo, B. Renga, M. Di Sante, A. Morelli, G. Cirino, and J.L. Wallace Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs Gastroenterology 129 2005 1210 1224
9. R.C. Zanardo, V. Brancaleone, E. Distrutti, S. Fiorucci, G. Cirino, and J.L. Wallace Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation FASEB J 20 2006 2118 2120
10. - secretion Curr Med Chem 19 2012 43 54
11. J.L. Wallace, R.W. Blackler, M.V. Chan, G.J. Da Silva, W. Elsheikh, K.L. Flannigan, I. Gamaniek, A. Manko, L. Wang, J.P. Motta, and A.G. Buret Anti-inflammatory and cytoprotective actions of hydrogen sulfide: translation to therapeutics Antiox Redox Signal 2014 (in press)
12. S.A. Mard, H. Askari, N. Neisi, and A. Veisi Antisecretory effect of hydrogen sulfide on gastric acid secretion and the involvement of nitric oxide Biomed Res Int 2014 2014 480921
13. L. Maiden, B. Thjodleifsson, A. Theodors, J. Gonzalez, and I. Bjarnason A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy Gastroenterology 128 2005 1172 1178
14. D.Y. Graham, A.R. Opekun, F.F. Willingham, and W.A. Qureshi Visible small-intestinal mucosal injury in chronic NSAID users Clin Gastroenterol Hepatol 3 2005 55 59
15. I. Watari, S. Oka, S. Tanaka, T. Aoyama, H. Imagawa, T. Shishido, S. Yoshida, and K. Chayama Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy: a pilot randomized controlled study BMC Gastroenterol 13 2013 108
16. R. Blackler, S. Syer, M. Bolla, E. Ongini, and J.L. Wallace Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence PLoS ONE 7 2012 e35196
17. J.L. Wallace Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy World J Gastroenterol 19 2013 1861 1876
18. T. Watanabe, T. Tanigawa, Y. Nadatani, Y. Nagami, S. Sugimori, H. Okazaki, and H. Yamagami Risk factors for severe nonsteroidal anti-inflammatory drug-induced small intestinal damage Dig Liver Dis 45 2013 390 395
19. A. LoGuidice, B.D. Wallace, L. Bendel, M.R. Redinbo, and U.A. Boelsterli Pharmacologic targeting of bacterial β-glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in mice J Pharmacol Exp Ther 341 2012 447 454
20. K.S. Saitta, C. Zhang, K.K. Lee, K. Fujimoto, M.R. Redinbo, and U.A. Boelsterli Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics Xenobiotica 44 2014 28 35
21. J.L. Wallace, G. Caliendo, V. Santagada, and G. Cirino Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346) Br J Pharmacol 159 2010 1236 1246
22. H. Satoh, K. Amagase, and K. Takeuchi Mucosal protective agents prevent exacerbation of NSAID-induced small intestinal lesions caused by antisecretory drugs in rats J Pharmacol Exp Ther 348 2014 227 335
23. J. Wax, W.A. Clinger, P. Varner, P. Bass, and C.V. Winder Relationship of the enterohepatic cycle to ulcerogenesis in the rat small bowel with flufenamic acid Gastroenterology 58 1970 772 780
24. M. Uejima, T. Kinouchi, K. Kataoka, I. Hiraoka, and Y. Ohnishi Role of intestinal bacteria in ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug Microbiol Immunol 40 1996 553 560
25. S. Seitz, and U.A. Boelsterli Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats Gastroenterology 115 1998 1476 1482
26. M. Hagiwara, K. Kataoka, H. Arimochi, T. Kuwahara, and Y. Ohnishi Role of unbalanced growth of gram-negative bacteria in ileal ulcer formation in rats treated with a nonsteroidal anti-inflammatory drug J Med Invest 51 2004 43 51
27. M. Jacob, R. Foster, G. Sigthorsson, R. Simpson, and I. Bjarnason Role of bile in pathogenesis of indomethacin-induced enteropathy Arch Toxicol 81 2007 291 298
28. K. Shindo, and M. Fukumura Effect of H2-receptor antagonists on bile acid metabolism J Investig Med 43 1995 170 177
29. K. Shindo, M. Machida, M. Fukumura, K. Koide, and R. Yamazaki Omeprazole induces altered bile acid metabolism Gut 42 1998 266 271
30. C. Williams, and K.E. McColl Review article: proton pump inhibitors and bacterial overgrowth Aliment Pharmacol Ther 23 2006 3 10
31. L. Lombardo, M. Foti, O. Ruggia, and A. Chiecchio Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy Clin Gastroenterol Hepatol 8 2010 504 508
32. M. Begley, C.G. Gahan, and C. Hill The interaction between bacteria and bile FEMS Microbiol Rev 29 2005 625 651
33. A.F. Hofmann The continuing importance of bile acids in liver and intestinal disease Arch Intern Med 159 1999 2647 2658
34. O. Martinez-Augustin, and F. Sanchez de Medina Intestinal bile acid physiology and pathophysiology World J Gastroenterol 14 2008 5630 5640